Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.

@article{Schott2013PreclinicalAC,
  title={Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.},
  author={Anne F. Schott and Melissa D. Landis and Gabriela Dontu and Kent A. Griffith and Rachel M. Layman and Ian Krop and Lacey A. Paskett and Helen Y Wong and Lacey E Dobrolecki and Michael T. Lewis and Amber M. Froehlich and Jaya Paranilam and Daniel F. Hayes and Max S. Wicha and Jenny C. Chang},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 6},
  pages={1512-24}
}
PURPOSE Accumulating evidence supports the existence of breast cancer stem cells (BCSC), which are characterized by their capacity to self-renew and divide indefinitely and resistance to conventional therapies. The Notch pathway is important for stem cell renewal and is a potential target for BCSC-directed therapy. EXPERIMENTAL DESIGN Using human breast tumorgraft studies, we evaluated the impact of gamma secretase inhibitors (GSI) on the BCSC population and the efficacy of combining GSI with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…